Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CARA

Cara Therapeutics (CARA) Stock Price, News & Analysis

Cara Therapeutics logo

About Cara Therapeutics Stock (NASDAQ:CARA)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$13.29
$17.10
52-Week Range
N/A
Volume
237,144 shs
Average Volume
22,224 shs
Market Capitalization
$24.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive CARA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CARA Stock News Headlines

Man Who Called Nvidia at $1.10 Says Buy This Now...
In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new company could become the next to soar like Nvidia.tc pixel
Cara Therapeutics board approves 1-for-3 reverse stock split
See More Headlines

CARA Stock Analysis - Frequently Asked Questions

Cara Therapeutics, Inc. (NASDAQ:CARA) issued its quarterly earnings results on Wednesday, August, 14th. The biopharmaceutical company reported ($13.32) earnings per share for the quarter, missing the consensus estimate of ($9.72) by $3.60. The biopharmaceutical company earned $0.99 million during the quarter, compared to analyst estimates of $1.26 million. Cara Therapeutics had a negative trailing twelve-month return on equity of 367.97% and a negative net margin of 1,099.76%.

Shares of Cara Therapeutics reverse split before market open on Wednesday, April 16th 2025.The 1-3 reverse split was announced on Monday, April 14th 2025. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 15th 2025. An investor that had 100 shares of stock prior to the reverse split would have 33 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cara Therapeutics investors own include LIONS GATE ENTERTAINMENT CORP /CN/ (LGF.A), NVIDIA (NVDA), Canopy Growth (CGC), Advanced Micro Devices (AMD), Meta Platforms (META), First Solar (FSLR) and Tesla (TSLA).

Company Calendar

Last Earnings
8/14/2024
Today
9/02/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CARA
CIK
1346830
Employees
80
Year Founded
2004

Profitability

EPS (Trailing Twelve Months)
($21.01)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$118.51 million
Net Margins
-1,099.76%
Pretax Margin
-1,099.76%
Return on Equity
-367.97%
Return on Assets
-107.43%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.77
Quick Ratio
4.71

Sales & Book Value

Annual Sales
$7.14 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$12.58 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
4,574,000
Free Float
4,429,000
Market Cap
$24.33 million
Optionable
Optionable
Beta
0.41

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:CARA) was last updated on 9/2/2025 by MarketBeat.com Staff
From Our Partners